Aptorum Group Ltd Annual Report - How They Did This Year

I’ve put together this guide to help you understand Aptorum Group’s performance over the past year. Instead of digging through dense legal filings, we’ll break down the important details so you can decide if this company fits your portfolio.

1. What does this company do?

Aptorum is a clinical-stage biotech company focused on developing treatments for rare and infectious diseases. Their primary pipeline includes ALS-4, which targets Staphylococcus aureus infections, and SACT-1, a treatment for neuroblastoma. Additionally, they operate "Talem Medical," an outpatient clinic in Hong Kong that provides diagnostic testing and general consultations, contributing a small portion of the company's total revenue.

2. Financial performance

Aptorum is currently in a "burn phase," spending significantly more than it earns. For the year ending December 31, 2025, the company generated approximately $0.6 million in revenue from its clinic, while research and administrative expenses exceeded $12 million.

The company relies on equity offerings and debt to fund operations. While they held $3.5 million in cash at year-end—up from $0.9 million the previous year—auditors have noted that current cash reserves are insufficient to cover operations for the next 12 months without additional capital.

3. Major wins and changes

The company recently merged with DiamiR Biosciences, a move that signals a shift toward the high-growth diagnostics market through microRNA-based tests for brain diseases. Aptorum also integrated "Scipio" to streamline the SACT-1 program. These strategic moves aim to simplify the company’s structure and focus resources on their lead clinical trials and the development of SACT-1, which has received Orphan Drug Designation from the FDA.

4. Financial health & internal controls

The company reported a "material weakness" in its financial controls, citing a lack of sufficient staff with expertise in U.S. accounting and SEC reporting. While management is actively hiring consultants and training staff to address these gaps, they have acknowledged that these controls were ineffective as of December 31, 2025. This creates a risk of reporting errors, which could impact regulatory standing, Nasdaq listing status, and investor confidence.

5. Key risks

Biotech investment carries inherent risks, particularly regarding the success of drug trials. Beyond these, the company faces specific operational vulnerabilities:

• Product Liability: As the company advances into human trials, it faces potential legal exposure. Currently, the company does not maintain product liability insurance.
• Operational Fragility: The company lacks "key-man" insurance for its leadership and does not hold business interruption insurance. A disruption at a manufacturing facility could halt the entire pipeline.
• Global Headaches: Operations are subject to complexities from Brexit and currency fluctuations, as the company spends in various currencies while reporting in U.S. dollars.
• Cybersecurity: The company does not maintain real-time, off-site backups for all research data, creating a risk that a cyberattack could result in the permanent loss of proprietary work.

6. Future outlook

The coming year is defined by the integration of DiamiR and the continued funding of clinical trials for ALS-4 and SACT-1. Given the company's reliance on external financing, the ongoing need to strengthen its finance team, and the absence of certain insurance and data security safeguards, investors should approach this opportunity with a high degree of caution. Success is contingent upon the company's ability to secure further funding and successfully navigate the high-risk, high-reward nature of clinical drug development.